A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
20
about 3.4 years
18+
1 site in TX
What this study is about
This trial is testing if a special type of scan, called an Axumin PET-CT, can help doctors better identify real or false progression of brain tumors in patients undergoing immunotherapy. The goal is to see how well this scan compares to the standard way of checking for tumor changes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.18F-Fluciclovine (Axumin)
- 2.Undergo Pet Scan
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
imaging